Semaglutide - Medication and Pregnancy KB

Semaglutide

Exposed non-exposed, cohort studies

Study	Country Study period Study design	Data source	Exposure definition	Non-exposure definition	Exposition period	Sample size (exposed/unexposed) Or (case / control)	Remarks	Risk of bias
Kolding (Controls exposed to insulin) 2025	Denmark 2016 - 2023 retrospective cohort	Mother–child linkage of electronic charts from all hospitals in the Central Denmark Region, via a unique identifier from the Danish Civil Registration System.	Pregnancies exposed to semaglutide (ATC A10BJ06) during the first trimester (from the estimated conception date to 70 days after, corresponding to gestational age 12 0/7).	exposed to other treatment, sick Pregnancies exposed to insulin with no simultaneous use of semaglutide.	1st trimester	32 / 547	Exposed group: 27 used Ozempic (22 of these in combination with insulin), and five used Wegovy. Seventeen discontinued semaglutide in the first trimester, and 14 used semaglutide throughout all trimesters.
Kolding (Controls exposed to insulin) 2025	Denmark 2016 - 2023 retrospective cohort		Exposure to semaglutide (ATC A10BJ06) and/or insulin (ATC A10B) in first trimester (from the estimated conception date to 70 days after, corresponding to GA 12 0/7), pregnancy and neonatal outcomes and informations regarding diabetes were collected from the electronic patient record.		1st trimester	32 / 547
Kolding (Controls unexposed, general pop) 2025	Denmark 2016 - 2023 retrospective cohort	Mother–child linkage of electronic charts from all hospitals in the Central Denmark Region, via a unique identifier from the Danish Civil Registration System.	Pregnancies exposed to semaglutide (ATC A10BJ06) during the first trimester (from the estimated conception date to 70 days after, corresponding to gestational age 12 0/7).	unexposed (general population or NOS) Pregnancies unexposed to diabetes medications.	1st trimester	32 / 103843	Exposed group: 27 used Ozempic (22 of these in combination with insulin), and five used Wegovy. Seventeen discontinued semaglutide in the first trimester, and 14 used semaglutide throughout all trimesters.
Kolding (Controls unexposed, general pop) 2025	Denmark 2016 - 2023 retrospective cohort		Exposure to semaglutide (ATC A10BJ06) and/or insulin (ATC A10B) in first trimester (from the estimated conception date to 70 days after, corresponding to GA 12 0/7), pregnancy and neonatal outcomes and informations regarding diabetes were collected from the electronic patient record.		1st trimester	32 / 103843
Maya 2025	USA 2016 - 2025 retrospective cohort	The Mass General Brigham, an academic health system with 15 institutions serving the greater Boston area in Massachusetts, USA.	Singleton pregnancies with Semaglutide order in the electronic health record (EHR) between 3 years before and 90 days after conception.	unexposed (general population or NOS) Singleton pregnancies without Glucagon-like peptide-1 receptor agonist (GLP-1RA) medications recorded between 3 years before pregnancy and 90 days after conception.	3 months or more before pregnancy or1st trimester	247 / 741
Maya 2025	USA 2016 - 2025 retrospective cohort		Maternal medications were obtained in the electronic health record (EHR) from the Mass General Brigham Enterprise Data Warehouse and the Mass General Brigham Research. The exposed and unexposed classifications were validated through manual medical record review of a subset of exposed participants.		3 months or more before pregnancy or1st trimester	247 / 741

Case-control studies

Study	Country Study period Study design	Data source	Case	Control	Exposition	Exposition period	Sample size (exposed/unexposed) Or (case / control)	Remarks	Risk of bias

Risk of bias: : NA; : low; : moderate; : serious; : critical; : unclear;

Empty. There are no case-control studies available for this drug.

master protocol